Last updated: February 28, 2026
What is the Product?
NDC 68546-0477 corresponds to Remdesivir, marketed as Veklury. It is an antiviral drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in adult and pediatric patients requiring hospitalization. Remdesivir received full FDA approval in October 2020.
Market Overview
Current Market Size
- Estimated global COVID-19 antiviral market was valued at approximately $2.4 billion in 2022.
- The U.S. accounts for roughly 50% of the global drug sales, driven by high vaccination rates and hospital procurements.
- Remdesivir captured an estimated 60% of the U.S. COVID-19 inpatient antiviral market in 2022.
Key Competitors
| Drug |
Approval Date |
Indication |
Market Share (2022) |
Estimated Price (per vial) |
| Remdesivir (Veklury) |
October 2020 |
COVID-19 hospitalization |
60% |
$390-520 |
| Molnupiravir |
December 2021 |
Mild to moderate COVID-19 |
15% |
$700 (per course) |
| Paxlovid |
December 2021 |
Mild to moderate COVID-19 |
25% |
$530 (per course) |
Market Dynamics
- The demand for remdesivir is primarily driven by COVID-19 hospitalization rates.
- New variants may affect treatment protocols and demand.
- Alternative oral antivirals like Paxlovid and Molnupiravir are increasingly prescribed for non-hospitalized patients, impacting remdesivir’s market share.
Market Trends
- Supply Chain: Production capacity expanded during 2021 and 2022, reducing per-unit costs.
- Pricing Trends: Prices remain relatively stable but could decline due to increased competition and generic manufacturing.
- Regulatory Developments: Some countries are considering extensions of remdesivir's approval or broadening indications, potentially expanding market size.
Price Projections
Short-term (2023-2025)
- Average wholesale price (AWP) for a vial is expected to stay within the $390-$520 range.
- The U.S. government procurement agreements have maintained stable pricing through 2022.
- Price reductions of up to 15% possible due to biosimilar development and increased manufacturing capacity.
Mid-term (2025-2030)
- Multiple biosimilar candidates are in development, targeting FDA approval by 2027-2028.
- Price per vial could decrease to $250-$350 once biosimilars enter the market.
- Hospital and insurance reimbursement policies may influence retail prices, potentially lowering patient costs.
Long-term (2030+)
- Remdesivir’s patent expiration may lead to widespread biosimilar manufacturing.
- Price per vial may fall below $200, matching or undercutting current oral antivirals.
- Market may shift toward combination therapies or newer antiviral agents, affecting remdesivir’s market share.
Regulatory and Patent Considerations
- Patent protections likely expire around 2027, prompting biosimilar entries.
- Patent challenges and patent extensions are possible, depending on legal outcomes.
- Regulatory agencies may approve generics faster if tighter biosimilar pathways are established.
Investment and R&D Outlook
- Large pharmaceutical companies are investing in biosimilar development.
- R&D focus shifts toward combination therapies and oral antivirals for outpatient use.
- Manufacturers have an incentive to develop more cost-effective manufacturing processes for biosimilars.
Key Takeaways
- Remdesivir remains a significant player in the injectable COVID-19 treatment space, with stable but potentially declining pricing.
- Biosimilar development poses a risk to current pricing structures, with prices projected to fall considerably over the next decade.
- The evolving landscape of antiviral therapy, including oral agents, may diminish remdesivir's market share over time.
- Regulatory approvals, patent litigation, and manufacturing capacity will influence future prices and market entry.
5 FAQs
Q1: What factors will most influence remdesivir’s price drops?
Market entry of biosimilars, patent expiry, manufacturing cost reductions, and increased competition from oral antivirals.
Q2: How does remdesivir compare in price to oral COVID-19 antivirals?
Injectable remdesivir typically costs $390-$520 per vial, whereas oral therapies such as Paxlovid and Molnupiravir range around $530-$700 per course, often with different dosing regimens.
Q3: When are biosimilars likely to enter the market?
Depending on regulatory pathways and patent disputes, biosimilars might launch between 2027 and 2028.
Q4: Will remdesivir be used for indications beyond COVID-19?
Currently under investigation for other viral diseases, but FDA approval is limited to COVID-19. Future expansion depends on clinical trial outcomes.
Q5: What is the impact of recent COVID-19 variants on remdesivir demand?
Variants that cause more severe disease continue to sustain demand. Variants with milder symptoms or increased outpatient testing reduce hospitalizations, potentially decreasing remdesivir's usage.
References
- U.S. Food and Drug Administration. (2020). FDA approves first COVID-19 treatment. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-treatment
- MarketsandMarkets. (2023). COVID-19 Therapeutics Market by Compound, Route of Administration, Distribution Channel, and Region - Global Forecast to 2027.
- IQVIA. (2022). Sales Data for COVID-19 Antivirals.
- FDA. (2023). Remdesivir (Veklury) Prescribing Information.
- BioPharm Insight. (2022). Biosimilar Development Pipeline Analysis.
